Lead Product(s) : ARO-INHBE,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Arrowhead Showcases RNAi Candidates for Obesity, Metabolic Disorders
Details : ARO-INHBE is a RNAi-based candidate, is designed to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E, being developed for obesity and metabolic diseases.
Product Name : ARO-INHBE
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
March 06, 2025
Lead Product(s) : ARO-INHBE,Tirzepatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ARO-INHBE
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for Obesity Treatment
Details : ARO-INHBE, a RNAi-based candidate, is designed to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E, being developed for obesity and metabolic diseases.
Product Name : ARO-INHBE
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
December 23, 2024
Lead Product(s) : ARO-INHBE
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MET-097i,MET-233i
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I/ Phase II
Sponsor : Altasciences Company Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Altasciences Supports Metsera in Their Early-Stage Clinical Trials for Obesity
Details : ET-097i is an ultra-long-acting injectable amylin analog, fully biased GLP-1 receptor agonist, being investigated in patients with obesity.
Product Name : MET-097i
Product Type : Peptide
Upfront Cash : Inapplicable
November 21, 2024
Lead Product(s) : MET-097i,MET-233i
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I/ Phase II
Sponsor : Altasciences Company Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MET-097i,MET-233i
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I/ Phase II
Sponsor : Wellington Management
Deal Size : $215.0 million
Deal Type : Series B Financing
Metsera Secures $215 Million Series B Financing to Further Accelerate Portfolio
Details : The proceeds will be used to further advance its portfolio of NuSH analog peptides, including MET-097i, a novel, fully-biased, potential once-monthly subcutaneously injectable GLP-1 RA.
Product Name : MET-097i
Product Type : Peptide
Upfront Cash : Undisclosed
November 13, 2024
Lead Product(s) : MET-097i,MET-233i
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I/ Phase II
Sponsor : Wellington Management
Deal Size : $215.0 million
Deal Type : Series B Financing
Lead Product(s) : GSBR-1290
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Structure Therapeutics Doses First Patients in Phase 2b GSBR-1290 Study
Details : GSBR-1290 is an orally-available small molecule agonist of the GLP-1 receptor, a validated drug target which is being evaluated for the treatment of Type 2 Diabetes Mellitus (T2DM) and obesity.
Product Name : GSBR-1290
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 13, 2024
Lead Product(s) : GSBR-1290
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GSBR-1290
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Structure Therapeutics Reports Positive Data from Phase 2a Obesity Study
Details : GSBR-1290 is a oral non-peptide small molecule GLP-1 receptor agonist which is being evaluated for the treatment of Obesity.
Product Name : GSBR-1290
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 06, 2024
Lead Product(s) : GSBR-1290
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabinoid
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ART27.13 (synthetic cannabinoid) is a highly potent, peripherally restricted synthetic, dual G-Protein Couple Receptor agonist believed to target the cannabinoid receptors CB1 and CB2, which has the potential to increase appetite and food intake.
Product Name : ART27.13
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 25, 2023
Lead Product(s) : Cannabinoid
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabinoid
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ART27.13 (synthetic cannabinoid)is a highly potent, peripherally restricted synthetic, dual G-Protein Couple Receptor agonist believed to target the cannabinoid receptors CB1 and CB2 , which has the potential to increase appetite and food intake.
Product Name : ART27.13
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 02, 2023
Lead Product(s) : Cannabinoid
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabinoid
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The mild to moderate adverse events observed in CAReS that have been attributed to ART27.13 (synthetic cannabinoid) required no dose reductions or terminations and many of the adverse events required no medical intervention at all.
Product Name : ART27.13
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 19, 2022
Lead Product(s) : Cannabinoid
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabinoid
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ART12.11 is a proprietary cocrystal composition of cannabidiol known to exhibit solid polymorphism, or the ability to manifest in different forms, develop treatments for people living with cancer, pain, and neurological conditions.
Product Name : ART27.13
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 03, 2022
Lead Product(s) : Cannabinoid
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable